Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin, founded in 2004. The company is focused on the discovery, development, and commercialization of novel technologies for cognitive support and other health challenges associated with aging. Quincy Bioscience stands out with its cutting-edge application of apoaequorin, which was originally discovered in jellyfish and is now patented for use in various products to support cognitive function. Apoaequorin, manufactured in a cGMP compliant facility, achieved self-affirmed GRAS status after being deemed safe for use in food products by an independent panel of expert scientists.

The company's flagship consumer brand, Prevagen, contains apoaequorin and has demonstrated the ability to improve cognitive function in participants with normal cognitive aging or very mild impairment. Prevagen has become the best-selling brain health supplement in chain pharmacies across America according to Nielsen data. In 2011, Quincy Bioscience secured a $239.00K venture round investment to support its growth and development efforts.

Quincy Bioscience's focus on innovative biotechnology solutions and its success in the cognitive support market demonstrate its potential for growth and impact in the healthcare industry. With its unique approach to utilizing apoaequorin and the market success of Prevagen, the company presents an intriguing opportunity for venture capital investment.